BB Biotech AG (BION.SW)
CHF 36.75
(0.68%)
CHF 36.75
(0.68%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | -199.56 Million CHF | 6.68% |
| 2022 | 6.52 Million CHF | -23.44% |
| 2021 | 8.52 Million CHF | 6.73% |
| 2020 | 7.98 Million CHF | 3.17% |
| 2019 | 7.73 Million CHF | 40.22% |
| 2018 | 5.51 Million CHF | 0.84% |
| 2017 | 5.47 Million CHF | -1.35% |
| 2016 | 5.54 Million CHF | -12.37% |
| 2015 | 6.33 Million CHF | 2.61% |
| 2014 | 6.17 Million CHF | 4.19% |
| 2013 | 5.92 Million CHF | -31.83% |
| 2012 | 8.68 Million CHF | -86.38% |
| 2011 | 63.78 Million CHF | -56.86% |
| 2010 | 147.85 Million CHF | 1379.54% |
| 2009 | 9.99 Million CHF | -64.8% |
| 2008 | 28.39 Million CHF | 1.55% |
| 2007 | 27.95 Million CHF | 109.06% |
| 2006 | -308.62 Million CHF | 4.88% |
| 2005 | -324.45 Million CHF | -2611.61% |
| 2004 | 12.91 Million CHF | -11.31% |
| 2003 | 14.56 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 7.46 Million CHF | -2036.42% |
| 2024 Q1 | 1.75 Million CHF | -13.08% |
| 2024 Q2 | 7.73 Million CHF | 340.71% |
| 2023 FY | 6.96 Million CHF | 6.68% |
| 2023 Q4 | 2.01 Million CHF | -73.69% |
| 2023 Q3 | 7.67 Million CHF | -12.72% |
| 2023 Q2 | 8.78 Million CHF | 403.67% |
| 2023 Q1 | 1.74 Million CHF | 11.64% |
| 2022 FY | 6.52 Million CHF | -23.44% |
| 2022 Q4 | 1.56 Million CHF | -84.87% |
| 2022 Q2 | 10.52 Million CHF | 478.82% |
| 2022 Q3 | 10.33 Million CHF | -1.81% |
| 2022 Q1 | 1.81 Million CHF | -99.49% |
| 2021 FY | 8.52 Million CHF | 6.73% |
| 2021 Q1 | 2.09 Million CHF | -85.93% |
| 2021 Q2 | 14.65 Million CHF | 599.0% |
| 2021 Q3 | 15.48 Million CHF | 5.64% |
| 2021 Q4 | 358.38 Million CHF | 2214.41% |
| 2020 Q3 | 12.2 Million CHF | 8.05% |
| 2020 FY | 7.98 Million CHF | 3.17% |
| 2020 Q4 | 14.89 Million CHF | 22.07% |
| 2020 Q2 | 11.29 Million CHF | 0.6% |
| 2020 Q1 | 11.22 Million CHF | -14.58% |
| 2019 Q4 | 13.14 Million CHF | -96.56% |
| 2019 Q2 | 34.53 Million CHF | -88.9% |
| 2019 Q1 | 311.16 Million CHF | -29.1% |
| 2019 FY | 7.73 Million CHF | 40.22% |
| 2019 Q3 | 381.6 Million CHF | 1004.94% |
| 2018 Q4 | 438.87 Million CHF | 3666.56% |
| 2018 Q2 | 99.31 Million CHF | 285.21% |
| 2018 FY | 5.51 Million CHF | 0.84% |
| 2018 Q1 | 25.78 Million CHF | 118.79% |
| 2018 Q3 | 11.65 Million CHF | -88.27% |
| 2017 Q4 | 11.78 Million CHF | 23.91% |
| 2017 Q3 | 9.5 Million CHF | -1.84% |
| 2017 Q2 | 9.68 Million CHF | 444.58% |
| 2017 FY | 5.47 Million CHF | -1.35% |
| 2017 Q1 | 1.77 Million CHF | 13.75% |
| 2016 Q4 | 1.56 Million CHF | -81.47% |
| 2016 Q1 | 1.95 Million CHF | 36.38% |
| 2016 Q3 | 8.44 Million CHF | -5.95% |
| 2016 FY | 5.54 Million CHF | -12.37% |
| 2016 Q2 | 8.97 Million CHF | 358.56% |
| 2015 Q3 | 10.98 Million CHF | 3.1% |
| 2015 FY | 6.33 Million CHF | 2.61% |
| 2015 Q4 | 1.43 Million CHF | -86.94% |
| 2015 Q2 | 10.65 Million CHF | 365.82% |
| 2015 Q1 | 2.28 Million CHF | 1.02% |
| 2014 Q4 | 2.26 Million CHF | -65.4% |
| 2014 Q3 | 6.54 Million CHF | 5.75% |
| 2014 Q2 | 6.19 Million CHF | 311.91% |
| 2014 FY | 6.17 Million CHF | 4.19% |
| 2014 Q1 | 1.5 Million CHF | -28.09% |
| 2013 Q2 | 5.64 Million CHF | 327.1% |
| 2013 Q3 | 5.09 Million CHF | -9.73% |
| 2013 Q4 | 2.09 Million CHF | -58.96% |
| 2013 FY | 5.92 Million CHF | -31.83% |
| 2013 Q1 | 1.32 Million CHF | 122.69% |
| 2012 Q2 | 4.75 Million CHF | -15.24% |
| 2012 Q3 | 4.66 Million CHF | -1.81% |
| 2012 Q4 | -5.82 Million CHF | -224.81% |
| 2012 Q1 | 5.6 Million CHF | 105.09% |
| 2012 FY | 8.68 Million CHF | -86.38% |
| 2011 Q3 | 127.54 Million CHF | 5172.55% |
| 2011 Q1 | 2.39 Million CHF | 103.84% |
| 2011 FY | 63.78 Million CHF | -56.86% |
| 2011 Q4 | -110.04 Million CHF | -186.28% |
| 2011 Q2 | 2.41 Million CHF | 0.96% |
| 2010 Q3 | 3.52 Million CHF | -98.77% |
| 2010 Q4 | -62.41 Million CHF | -1869.72% |
| 2010 Q1 | 2.12 Million CHF | -24.47% |
| 2010 FY | 147.85 Million CHF | 1379.54% |
| 2010 Q2 | 286.19 Million CHF | 13399.91% |
| 2009 Q2 | 811 Thousand CHF | -27.13% |
| 2009 Q3 | 3.33 Million CHF | 311.1% |
| 2009 Q4 | 2.8 Million CHF | -15.81% |
| 2009 FY | 9.99 Million CHF | -64.8% |
| 2009 Q1 | 1.11 Million CHF | 0.0% |
| 2008 FY | 28.39 Million CHF | 1.55% |
| 2007 FY | 27.95 Million CHF | 109.06% |
| 2006 FY | -308.62 Million CHF | 4.88% |
| 2005 FY | -324.45 Million CHF | -2611.61% |
| 2004 FY | 12.91 Million CHF | -11.31% |
| 2003 FY | 14.56 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Addex Therapeutics Ltd | 11.89 Million CHF | 1777.844% |
| Basilea Pharmaceutica AG | 111.63 Million CHF | 278.767% |
| Evolva Holding SA | 89.66 Million CHF | 322.575% |
| Idorsia Ltd | 400.38 Million CHF | 149.844% |
| Kuros Biosciences AG | 36.21 Million CHF | 651.001% |
| Molecular Partners AG | 20.3 Million CHF | 1082.992% |
| Relief Therapeutics Holding AG | 114.94 Million CHF | 273.626% |
| Santhera Pharmaceuticals Holding AG | 31.33 Million CHF | 736.882% |